Scynexis, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1999)

Organization Overview

First Clinical Trial
2007
NCT01290965
First Marketed Drug
2021
scy-078
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SCYNEXIS | Scynexis, Inc.

Active Ingredients

Marketed Drugs (1)

scy-078 (2021)

Drugs in Phase 3 Trials (2)

fluconazole (diflucan) (5 trials)

scy-078 (15 trials)

Drugs in Phase 2 Trials (5)

interferon alpha-2b (Intron-A) (1 trial)

micafungin (mycamine) (1 trial)

ribavirin (virazole) (1 trial)

scy-635 (2 trials)

voriconazole (vfend) (1 trial)

Drugs in Phase 1 Trials (2)

dabigatran (pradaxa) (1 trial)

pravastatin (pravachol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aspergillosis (Phase 3)

Aspergillosis, Allergic Bronchopulmonary (Phase 3)

Blastomycosis (Phase 3)

Candidemia (Phase 3)

Candidiasis (Phase 3)

Candidiasis, Chronic Mucocutaneous (Phase 3)

Candidiasis, Invasive (Phase 3)

Candidiasis, Vulvovaginal (Phase 3)

Coccidioidomycosis (Phase 3)

Coccidiosis (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

Histoplasmosis (Phase 3)

Infections (Phase 2)

Invasive Pulmonary Aspergillosis (Phase 3)

Mycoses (Phase 3)

Pulmonary Aspergillosis (Phase 3)

Vulvovaginitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 9